Dose-response to salbutamol via a novel palm sized nebuliser (Aerodose® Inhaler), conventional nebuliser (Pari LC Plus) and metered dose inhaler (Ventolin™ Evohaler™) in moderate to severe asthmatics

British Journal of Clinical Pharmacology

Volumn 59, Issue 1, 2005, Pages 5-13

  Lipworth, Brian J ^a,c   Sims, Erika J ^a   Taylor, Karla ^b   Cockburn, Wendy ^a   Fishman, Robert ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b Aerogen Incorporated   (United States)

^c Dept of Allerg and Resp Medicine ^*  (United Kingdom)

Author keywords

Asthma; Inhalation devices; Salbutamol

Indexed keywords

POTASSIUM; SALBUTAMOL;

ADULT; ARTICLE; ASTHMA; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOSE RESPONSE; DRUG POTENCY; FEMALE; FORCED EXPIRATORY VOLUME; HEART RATE; HUMAN; INTERMETHOD COMPARISON; MALE; METERED DOSE INHALER; NEBULIZER; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; QT INTERVAL; QTC INTERVAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SINGLE BLIND PROCEDURE; SPIROMETRY; T WAVE;

ADMINISTRATION, INHALATION; ADULT; ALBUTEROL; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; EQUIPMENT DESIGN; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; METERED DOSE INHALERS; SINGLE-BLIND METHOD; VITAL CAPACITY;

EID: 11144290017     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02168.x     Document Type: Article

References (22)

1. National Institutes of Health. National Asthma Education and Prevention Programme. Expert Panel Report II. Guidelines for the Diagnosis and Management of Asthma. 1997. Publication no. 97-4053, Bethesda, MD 97. A.D. Ref Type: Generic.
2. Mason JW, Miller WC. Abbreviated aerosol therapy for improved efficiency. Aerosol Med 1998; 11: 127-31.
3. Hultquist C, Wollmer P, Eklundh G, et al. Effect of inhaled terbutaline sulphate in relation to its deposition in the lungs. Pulm Pharmacol 1992; 5: 127-32.
4. Young LY. Handbook of Applied Therapeutics. Vancouver, Washington: Applied Therapeutics, Inc 1996.
5. Lipworth BJ, Newnham DM, Clark RA, et al. Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients. Thorax 1995; 50: 54-61.
6. Pearlman DS, Chervinsky P, Laforce C, et al. A comparison of salmeterol with salbutamol in a treatment of mild to moderate asthma. N Engl J Med 1992; 327: 1420-5.
7. Fowler SJ, Lipworth BJ. Pharmacokinetics and systemic beta2-adrenoceptor-mediated responses to inhaled salbutamol. Br J Clin Pharmacol 2001; 51 (4): 359-62.
8. Bremner P, Burgess C, Beasley R, et al. Nebulized fenoterol causes greater cardiovascular and hypokalaemic effects than equivalent bronchodilator doses of salbutamol in asthmatics. Respir Med 1992; 86 (5): 419-23.
9. Lipworth BJ, McDevitt DG. Beta-adrenoceptor responses to inhaled salbutamol in normal subjects. Eur J Clin Pharmacol 1989; 36: 239-45.
10. Devadason SG, Everard ML, Linto JM, et al. Comparison of drug delivery from conventional versus 'Venturi' nebulizers. Eur Respir J 1997; 10 (11): 2479-83.
11. Simon M, Mar D, Uster P, et al. Aerosol characteristics of the AeroDose® inhaler with salbutamol sulfate: an. In Vito evaluation. Chest 120 2001, 225S: Ref. Type: (Abstract).
12. Fink J, Dhand R. Bronchodilator resuscitation in the emergency department. Part 2 of 2: dosing strategies. Respir Care 2000; 45 (5): 497-512.
13. Data held on file. AeroGen Inc., Sunnyvale, CA 94089 USA 2002: Ref Type: Data File.
14. Everard ML, Devadason SG, Summers QA, et al. Factors affecting total and 'respirable' dose delivered by a salbutamol metered dose inhaler. Thorax 1995; 50 (7): 746-9.
15. Lipworth BJ. Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol 1996; 42: 697-705.
16. Newman SP, Pitcairn GR, Hooper G, et al. Efficient drug delivery to the lungs from a continuously operated open- vent nebulizer and low pressure compressor system. Eur Respir J 1994; 7 (6): 1177-81.
17. Zainudin BM, Biddiscombe M, Tolfree SE, et al. Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution. Thorax 1990; 45 (6): 469-73.
18. Eiser N, Angus K, McHale S. The role of domiciliary nebulizers in managing patients with severe COPD. Respir Med 2001; 95 (4): 265-74.
19. Barry PW, O'Callaghan C. An in vitro analysis of the output of salbutamol from different nebulizers. Eur Respir J 1999; 13 (5): 1164-9.
20. Fowler SJ, Lipworth BJ. Therapeutic equivalence of inhaled salbutamol. Thorax 2000; 55 (4): 347-8.
21. Barry PW, O'Callaghan C. The output of budesonide from nebulizers. J Allergy Clin Immunol 1998; 102 (2): 321-2.
22. Faurisson F, Dessanges JF, Grimfeld A, et al. Nebulizer performance: AFLM study. Association Francaise de Lutte contre la Mucoviscidose. Respiration 1995; 62(Suppl 1): 13-8.